Invivyd, Inc. · NASDAQ:IVVD
Invivyd — Technical Presentation (2022)
4 slides from Invivyd's technical presentation, 2022
Slide 1: Results from the Phase 2/3 Randomized, Double-Blind, Placebo-Controlled Trial of Adintrevimab (STAMP)
Results from the Phase 2/3 Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Adintrevimab (ADG20) in the Treatment of Ambulatory Participants with Mild or Moderate COVID-19 (STAMP) Myra Popejoy1, Kathryn Mahoney1, Natalia Betancourt1, Yong Li1, Deepali Gupta1,
Slide 2: Adintrevimab (ADG20), a monoclonal antibody targeting the SARS-CoV-2 spike protein
Adintrevimab (ADG20), a monoclonal antibody designed to target the SARS-CoV-2 spike protein, is being evaluated for the treatment and prevention of COVID-19 • Adintrevimab was derived from a The STAMP trial (NCT04805671) is evaluating the safety and efficacy of adintrevimab as a survivor of the 2003
Slide 3: Adintrevimab met primary objective with 66% relative risk reduction in non-Omicron population
Adintrevimab met the trial's primary objective with relative risk of hospitalization or death reduced by 66% compared to placebo among non-Omicron population COVID-19–related hospitalization or all-cause death through Adjusted mean change from baseline in SARS-CoV-2 viral load (log10 copies/mL) day
Slide 4: Safety data and conclusions
Safety data and conclusions Adintrevimab Placebo Overall N=192 N=200 N=392 Participants with any n (%) n (%) n (%) Any TEAE 51 (26.6) 72 (36.0) 123 (31.4) Unsolicited TEAE 36 (18.8) 56 (28.0) 92 (23.5) Solicited TEAE (Injection Site Reactions) 25 (13.0) 20 (10.0) 45 (11.5) Study Drug-Related TEAE 26
Invivyd — Technical Presentation (2022) on 6ix